Arbutus Presents HBV Data at Upcoming Scientific C
Post# of 301275
VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS ), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of HBV data at the following scientific conferences.
Discovery on Target: Targeting HBV, Sept 25, 2017, Boston, MA Presentations Include:
- RNA Interference: A New Tool in the Toolbox for Treatment of HBV by Amy Lee, Senior Director, Research
- HBV Capsid Assembly Inhibitors by Rene Rijnbrand, Vice President, Head of Biology
Discovery on Target: Emerging Oligonucleotide Therapeutics, Sept 27-28, 2017, Boston, MA Presentation Includes:
- RNAi Based Human Therapy for Chronic Hepatitis B Infection by Amy Lee, Senior Director, Research
These presentations will be available by visiting the Investor section of www.arbutusbio.com and selecting Events and Presentations.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com .
Contact Information
Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: acutler@arbutusbio.com
Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: ttolmie@arbutusbio.com
Media David Schull Russo Partners Phone: 858-717-2310 Email: david.schull@russopartnersllc.com
(0)
(0)